International Journal of Cardiology
Volume 129, Issue 3 , Pages 339-343, 13 October 2008

Sildenafil therapy in complex pulmonary atresia with pulmonary arterial hypertension

Congenital Cardiac Centre, Southampton University Hospital, United Kingdom

Received 4 July 2007; accepted 18 August 2007. published online 14 November 2007.

Abstract 

Background

Complex pulmonary atresia (CPA) i.e. pulmonary atresia with ventricular septal defect and major aorto-pulmonary collaterals (MAPCAs) or Tetralogy of Fallot with MAPCAs frequently have a clinical course complicated by development of pulmonary arterial (PA) hypertension.

Methods

A cross-sectional retrospective review of patients >16 years with CPA or Tetralogy of Fallot with MAPCAs and PA hypertension treated with sildenafil was conducted. Case notes were reviewed for baseline and follow-up (after sildenafil) characteristics.

Results

Five patients, 4 female, median age 28 (range 18 to 47) years, were identified. All patients experienced symptomatic improvement: 2 of 4 wheelchair bound patients responded dramatically and walked 345 and 157 m respectively in 6 min following sildenafil therapy. One of the 4 with marked PA arborization abnormalities and severe ventricular dysfunction had initial symptomatic improvement. Another patient improved from walking less 100 m to climbing 2 flights of stairs. Arterial saturations improved in 2 cases from 70 and 60% to 87 and 84% respectively, whilst arterial saturations remained static in 1 case despite embolization of a classical Blalock–Taussig shunt. One patient with PA arborization/diminished PA bed was unable to tolerate sildenafil.

Conclusions

Sildenafil is well tolerated and leads to symptomatic improvement and better saturations in the majority of patients with CPA with PA hypertension when used in isolation or as an adjunct to percutaneous PA angioplasty.

Abbreviations: PA, pulmonary artery, MAPCAs, Major aorto-pulmonary collateral arteries, CPA, complex pulmonary atresia.

Keywords: Pulmonary atresia, Congenital heart disease, Pulmonary hypertension, Cyanosis, Sildenafil

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 All authors declare that the answer to the questions on your competing interest form are all no and therefore have nothing to declare.

PII: S0167-5273(07)01677-4

doi:10.1016/j.ijcard.2007.08.016

International Journal of Cardiology
Volume 129, Issue 3 , Pages 339-343, 13 October 2008